ArticleFrontiers in oncology2026
Impact of the COVID-19 pandemic on ovarian cancer diagnosis, treatment, and survival in a Swiss tertiary care hospital - a conclusion five years after the outbreak of the pandemic.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The outbreak of SARS-CoV-2 in 2020 and the resulting lockdowns had a major impact on general healthcare provision. This study aimed to investigate whether the COVID-19 pandemic affected diagnosis, treatment, and survival of ovarian cancer patients at our institution. Methods: This retrospective cohort study included patients diagnosed with primary ovarian cancer and borderline ovarian tumor (BOT) at Bern University Hospital between January 2019 and December 2022. Clinical data were collected in a standardized database. Results: A total of 218 patients were included. Annual distribution of primary ovarian cancer diagnoses was 52 (2019), 32 (2020), 39 (2021), and 57 (2022), while borderline ovarian tumor diagnoses remained stable: 10 (2019, 2020, 2022) and 8 (2021). FIGO stage distribution remained unchanged during the study period (p= .520). Among 131 patients with advanced-stage ovarian cancer, 84% underwent cytoreductive surgery without significant changes over time (p= .838). However, a shift in surgical strategy was observed with interval debulking surgery increasing significantly during the COVID-19 pandemic years (2020 - 2021) (p= .030). Complete cytoreduction was achieved in 89% of cases, remaining constant (p= .355). Chemotherapy was administered to 94% of advanced-stage patients, with no changes during the COVID-19 pandemic years (p= .139). Cox regression analysis revealed no increased risk of recurrence (p= .142) or death (p= .587) for patients diagnosed during the COVID-19 pandemic years (2020-2021) compared to those in 2019 and 2022. Conclusion: While BOT diagnoses remained stable throughout the COVID-19 pandemic years, primary ovarian cancer diagnoses decreased in 2020 and 2021. No shift in disease stage was observed. However, more patients received interval debulking surgery during the pandemic. Overall, the SARS-CoV-2 outbreak did not negatively affect the oncological outcomes of patients with advanced-stage ovarian cancer at our institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.